Applications of monitoring platelet glycoprotein IIb/IIIa antagonism and low molecular weight heparin in cardiovascular medicine

American Heart Journal

Volumn 140, Issue 6 SUPPL., 2000, Pages

  Moliterno, David J ^a   Mukherjee, Debabrata ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FIBRINOGEN RECEPTOR ANTAGONIST; LOW MOLECULAR WEIGHT HEPARIN;

ARTICLE; BLEEDING; CORONARY ARTERY THROMBOSIS; DRUG EFFICACY; DRUG MECHANISM; DRUG MONITORING; DRUG SAFETY; HEART MUSCLE ISCHEMIA; HEART MUSCLE REVASCULARIZATION; HUMAN; PRIORITY JOURNAL;

EID: 0033669596     PISSN: 00028703     EISSN: None     Source Type: Journal    
DOI: 10.1067/mhj.2000.111608     Document Type: Article

References (9)

1. A prospective multicenter study to determine the optimal level of platelet inhibition with GPIIb/IIIa inhibitors in patients undergoing coronary intervention: GOLD study
2. Bedside platelet function testing
3. PFA-100 system: A new method for assessment of platelet dysfunction
4. Comparative effects of abciximab and integrilin on platelets and fibrin formation in native non-anticoagulated blood under flow conditions
5. Rapid and simple platelet function assay to assess glycoprotein IIb/IIIa receptor blockade
6. The accumetrics rapid platelet function analyzer (RPFA) to monitor platelet aggregation during oral administration of a GPIIb/IIIa antagonist
7. Efficacy of abciximab induced platelet blockade using a rapid point of care assay
8. Time course, magnitude, and consistency of platelet inhibition by abciximab, tirofiban, or eptifibatide in patients with unstable angina pectoris undergoing percutaneous coronary intervention
9. Attainment and maintenance of platelet inhibition through standard dosing of abciximab in diabetic and nondiabetic patients undergoing percutaneous coronary intervention